Tredegar Reports Third Quarter 2020 Results

Tredegar Corporation (NYSE:TG, also the “Company” or “Tredegar”) today reported third quarter financial results for the period ended September 30, 2020.

Third quarter 2020 net loss from continuing operations was $17.0 million ($0.51 per diluted share) compared to net income from continuing operations of $15.1 million ($0.45 per diluted share) in the third quarter of 2019. Net income from ongoing operations, which excludes special items and discontinued operations, was $13.2 million ($0.39 per diluted share) in the third quarter of 2020 compared with $13.3 million ($0.40 per diluted share) in the third quarter of 2019. A reconciliation of net income (loss) from continuing operations, a financial measure calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to net income from ongoing operations, a non-GAAP financial measure, for the three and nine months ended September 30, 2020 and 2019, is provided in Note (a) of the Notes to the Financial Tables in this press release.

On August 24, 2020, the Company entered into a definitive agreement to sell its Personal Care Films business (“Personal Care business”), which excludes the packaging film lines and related operations located at the Pottsville, Pennsylvania manufacturing site (“Pottsville Packaging”). The Company completed this divestiture at the end of October and received gross proceeds of $60.5 million. Net cash proceeds from the sale, after future deductions for transaction costs, purchase price adjustments and transition services after September 30, 2020, are estimated at $45 to $50 million. Net cash income tax costs or benefits relating to the transaction are expected to be negligible. All historical results for the Personal Care business have been presented as discontinued operations. The surface protection component of the PE Films segment now includes Pottsville Packaging.

Third Quarter Financial Results Highlights:
*Earnings before interest, taxes, depreciation and amortization (“EBITDA”) from ongoing operations for Aluminum Extrusions of $16.5 million was $0.1 million higher than the third quarter of 2019
*EBITDA from ongoing operations for PE Films of $6.0 million was $4.2 million lower than the third quarter of 2019
*EBITDA from ongoing operations for Flexible Packaging Films of $9.5 million was $5.2 million higher than the third quarter of 2019

John Steitz, Tredegar’s president and chief executive officer said, “Despite COVID-19-related lower volume, Bonnell Aluminum’s EBITDA from ongoing operations during the third quarter was essentially flat with last year. It continues to outperform our expectations. The PE Films segment experienced a decline in profitability during the third quarter versus last year due to previously disclosed customer product transitions in the Surface Protection component that had been delayed. Our Surface Protection team has been making progress in generating sales from new products, applications and customers to help offset the expected future adverse impact of the transitions. Regarding Terphane, our flexible packaging films business, its performance has been a great story since 2017, but especially in 2020 with EBITDA from ongoing operations doubling in 2020 versus 2019.”

Mr. Steitz continued, “We had strong cash flow during the third quarter with net cash in excess of debt as of September 30, 2020 of $28.0 million, up from $5.9 million as of June 30, 2020, which excludes the net cash proceeds expected from the sale of the Personal Care business of $45 to $50 million.”

On a final note, Mr. Steitz commented, “I’d like to thank again all of our employees for their hard work and dedication during these unprecedented times.”
details at: https://ir.tredegar.com/news-releases/news-release-details/tredegar-reports-third-quarter-2020-results

Related Posts

Huhtamäki Oyj’s Interim Report January 1 – March 31, 2021: Improved profitability due to gradual recovery in demand

Q1 2021 in brief * Net sales decreased by 5% to EUR 802 million. EUR (845 million) * Adjusted operating profit was MEUR 77. EUR (EUR 74 million); reported operating profit EUR 72 million EUR (83 million) * Adjusted earnings per share were EUR 0.49 (EUR 0.46); reported earnings per share EUR 0.45 (EUR 0.53) * Comparable revenue growth was -0% at Group level and 4% in emerging markets * The effect of exchange rate fluctuations on the Group's net sales was EUR -46 million. EUR -5 million in operating profit. euros

Grainger Reports Results for the First Quarter 2024

First Quarter Highlights *Delivered sales of $4.2 billion, up 3.5%, or 4.9% on a daily, organic constant currency basis *Achieved operating margin of 15.8%, down 80 basis points *Generated $661 million in operating cash flow and returned $360 million to Grainger shareholders through dividends and share repurchases. Grainger reported results for the first quarter of 2024 with sales of $4.2 billion, up 3.5%, or 4.9% on a daily, organic constant currency basis, and diluted EPS of $9.62, up 0.1% compared to the first quarter of 2023.

UPM Raflatac expands offering with new innovations for medical device and healthcare labeling

UPM Raflatac has further expanded its range of guaranteed, globally available, and compliant pharmaceutical and healthcare label materials for the medical device and healthcare industries. Today there are over 500,000 types of medical and in vitro diagnostic medical devices available in the EU, with a medical device meaning anything from a contact lens or sticking plaster to an x-ray machine or hip replacement component. In vitro diagnostic medical devices include things like HIV blood tests, pregnancy tests, and blood sugar monitoring systems for diabetics. The new RPMD (Raflatac Permanent Medical Device) adhesive range includes labeling solutions for drug/device combination products like insulin pens, auto-injectors, and inhalers, as well as blood donation labeling, sterilization pouches for medical devices, and infusion bags and bottles. Combining selected paper and film face materials with an RPMD adhesive ensures excellent adhesion with a tight mandrel hold on glass and plastic, as well as sterilization resistance and migration safety - both common requirements in medical device and healthcare labeling. Click Read More below for additional detail.
Back To Top
×Close search
Search